Protagonist Therapeutics Stock News

Protagonist Therapeutics is currently working to tackle some serious issues with an underserved form of blood cancer. A recent cancer scare sent shockwaves through the company's valuation, and it has

In this article we will check out the progression of hedge fund sentiment towards Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and determine whether it is a good investment right now.

Protagonist Therapeutics (NASDAQ:PTGX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings. Profitability This table compares Protagonist Therapeutics and Syndax Pharmaceuticals net margins, return on equity and []

Wall Street brokerages expect that Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will report $7.38 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Protagonist Therapeutics earnings. The lowest sales estimate is $7.00 million and the highest is $7.50 million. Protagonist Therapeutics reported sales of $5.65 million during the same []

Equities analysts expect Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to report ($0.79) earnings per share for the current quarter, according to Zacks. Four analysts have provided estimates for Protagonist Therapeutics earnings. The highest EPS estimate is ($0.70) and the lowest is ($0.97). Protagonist Therapeutics posted earnings of ($0.48) per share during the same quarter last year, which []

Jabodon PT Co. purchased a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the third quarter, HoldingsChannel.com reports. The institutional investor purchased 90,656 shares of the companys stock, valued at approximately $1,606,000. Protagonist Therapeutics makes up about 0.7% of Jabodon PT Co.s investment portfolio, making the stock its 25th biggest position. Several other []

Millennium Management LLC lifted its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 41.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 15,440 shares of the company’s stock after purchasing an additional 4,548 shares during the period. Millennium Management LLC’s holdings in Protagonist Therapeutics were worth $693,000 as […]

Invesco Ltd. increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 79.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,122 shares of the companys stock after buying an additional 8,019 shares during the quarter. Invesco Ltd.s holdings in Protagonist Therapeutics were worth $814,000 []

Protagonist Therapeutics Inc. (NASDAQ:PTGX) price on Friday, December 10, fall -1.76% below its previous days close as a downside momentum from buyers pushed the stocks value to $31.81. A look at the stocks price movement, the close in the last trading session was $32.38, moving within a range at $31.68 and $33.06. The beta value Protagonist Therapeutics Inc. (PTGX) Outlook: Looking Back For Insights Read More »

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has been given a consensus recommendation of Buy by the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12-month target price among brokers []

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases Drug And Focus On PN-235 P

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases Drug And Focus On PN-235 Protagonist Therapeutics (NASDAQ: PTGX ) said it has selected PN-235 as the final candidate for all clinical studies in multiple indications based on intervention of the Interleukin-23 pathway, under its collaboration with Johnson & Johnson, Inc.''s (NYSE: JNJ ) Janssen unit. In addition to the previously announced Phase 2 clinical study of PN-235 in psoriasis, new Phase 2 clinical studies of PN-235 in inflammatory bowel diseases are expected to commence in late 2022. Further development of PN-232 will be discontinued in favor of PN-235 based on its superior potency, and overall pharmacokinetic and pharmacodynamic profile, the company added. The stock was down 3.64% to $31.50 in premarket trading. Click here to access Benzinga''s FDA Calendar Bristol-Myers Squibb Says Application For Expanding Label For Reblozyl Accepted For Priority Review Bristol-Myers Squibb Company (NYSE: BMY ) announced that the U.S.

Protagonist Therapeutics Inc (NASDAQ: PTGX) has selected PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on the intervention of the Interleukin-2

NEWARK, Calif., Dec. 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.